Bitterman Robert J 4

What Happened

• Robert J. Bitterman, Phio Pharmaceuticals' Chairman, President & CEO, reported an open-market purchase of 10,000 shares of PHIO common stock on 2026-06-26 at $0.99 per share, for a total of $9,900. This was a purchase (transaction code P), which is generally more informative than routine sales but the dollar amount is modest.

Key Details

• Transaction date and price: 2026-06-26 — 10,000 shares at $0.99/share.
• Total value: ~$9,900.
• Transaction type: Open-market purchase (Code P).
• Shares owned after transaction: Not specified in the supplied filing.
• Footnote: F1 — Includes shares underlying unvested restricted stock units (these count toward beneficial ownership but may not be vested).
• Filing timeliness: Form 4 filed 2026-06-29 (filed within the required two business days), so the report appears timely.

Context

• Small-dollar insider purchases like this can show insider participation but are limited in scale; they are factual disclosures and do not by themselves prove future company performance.
• The footnote clarifies that the insider's reported holdings may include unvested RSUs, which are different from immediately tradable shares.